Having failed with orlotamab, and with enoblituzumab’s potential narrowing, Macrogenics generates interest around MGC018.
Boehringer says its inhaled antibody could reach the patients IV antibodies cannot, but will be “very happy” if it isn’t needed.
Attempts to improve the Alzheimer’s disease project’s chance of success are understandable, but the market has moved on for now.
Full data on Lilly's Alzheimer’s antibody will disappoint some, and point to a long road ahead.
A win for Vir’s late-to-the-game antibody and another fail for Roche with Actemra show how developers are still feeling their way in Covid-19.
Tecentriq follows Opdivo, Imfinzi and Keytruda in having a US approved use knocked out.
There might be a use for Glaxo’s anti-Covid-19 antibody otilimab in old patients, but repeating Actemra’s trick will not be easy.